Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Disappointing Pricing for China Nuokang’s Nasdaq IPO

publication date: Dec 10, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China Nuokang Bio-Pharmaceutical priced its IPO at $9, which was slightly below the expected range of $10-$12. When the shares began trading today, they fell further, dropping 56 cents to $8.44, a loss of about 6%. The company receives 94% of its revenues from a single product, the hemocoagulant Baqueting, which is derived from the venom of the pit viper. More details...

Stock Symbol: (NSDQ: NKBP)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners